• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

QleanAir signs two new US cleanroom agreements totaling approximately $2.4 million USD, adding a specialty compounding partner and continuing work with a longstanding institutional customer

QAIRPress release27.05.2026 klo 09.50
Discuss

QleanAir AB (publ), a leading provider of solutions for clean indoor air, has signed two new agreements with US healthcare customers for the construction of modular cleanrooms compliant with USP 797 and USP 800 standards. The agreements include a first cleanroom for a multi-state specialty compounding pharmacy operator, and a continued partnership with a longstanding institutional customer at a hospital in Texas. Both projects are scheduled to commence in 2026 and complete by the end of the first quarter of 2027.

QleanAir is dedicated to being an excellent partner through building and maintaining modular cleanrooms that exceed USP guidelines and maintain a compliant state of control.

The first agreement, valued at approximately $1.8 million USD, is for a sterile compounding fulfillment facility that includes a USP 797, USP 800, and cGMP-compliant microbiology laboratory. It marks the first QleanAir cleanroom for this customer, a multi-state specialty compounding pharmacy operator focused on personalized medicine, with operations across the Gulf South and the Midwest. The customer's parent organization operates in adjacent areas with significant cleanroom requirements, opening the door to a broader, multi-site partnership over time.

The second agreement, valued at approximately $551,000 USD, is for a USP 797 and USP 800 compliant compounding cleanroom at a hospital in Texas. The hospital is part of a large integrated healthcare system that QleanAir has supported across multiple sites, and the agreement extends a longstanding institutional relationship that has become a consistent source of repeat business.

Both cleanrooms are scheduled to begin construction in 2026 and complete by the end of the first quarter of 2027.

– “These two agreements reflect the breadth of our customer base in the United States. We are excited to begin a new partnership with a multi-state specialty compounding pharmacy operator that also has cleanroom needs across its parent organization, and we are honored to continue our work with a longstanding institutional customer that consistently turns to QleanAir for its compounding cleanroom needs” says Zachary Douglas, President of QleanAir Scandinavia Inc.

For more information, please contact:


Sebastian Lindström, CEO
sebastian.lindstrom@qleanair.com
+46 703 08 94 51

Fredrik Sandelin, CFO
fredrik.sandelin@qleanair.com
+46 722 09 61 67

About QleanAir


QleanAir is a niche premium provider of clean indoor environment solutions. The company’s business model is based on rental contracts for modular solutions with a full-service offer. QleanAir’s solutions are developed using filter technology that traps, filters and recycles indoor air. The company’s main markets are EMEA, APAC and the Americas. QleanAir’s head office is located in Solna, Sweden, and the share is traded on Nasdaq First North Premier Growth Market, ticker QAIR. FNCA Sweden is Certified Advisor. For more information go to qleanair.com.

Attachments


QleanAir signs two new US cleanroom agreements totaling approximately $2.4 million USD, adding a specialty compounding partner and continuing work with a longstanding institutional customer